Figg WD - Search Results

1

Current status of thalidomide and its role in the treatment of metastatic prostate cancer.

Macpherson GR, Franks M, Tomoaia-Cotisel A, Ando Y, Price DK, Figg WD. Macpherson GR, et al. Among authors: figg wd. Crit Rev Oncol Hematol. 2003 Jun 27;46 Suppl:S49-57. doi: 10.1016/s1040-8428(03)00064-7. Crit Rev Oncol Hematol. 2003. PMID: 12850527 Review.

2

Hypothyroidism associated with aminoglutethimide in patients with prostate cancer.

Figg WD, Thibault A, Sartor AO, Mays D, Headlee D, Calis KA, Cooper MR. Figg WD, et al. Arch Intern Med. 1994 May 9;154(9):1023-5. Arch Intern Med. 1994. PMID: 8179445

3

Severe thrombocytopenia in patients treated with suramin: evidence for an immune mechanism in one.

Tisdale JF, Figg WD, Reed E, McCall NA, Alkins BR, Horne MK 3rd. Tisdale JF, et al. Among authors: figg wd. Am J Hematol. 1996 Feb;51(2):152-7. doi: 10.1002/(SICI)1096-8652(199602)51:2<152::AID-AJH10>3.0.CO;2-K. Am J Hematol. 1996. PMID: 8579057 Free article. Clinical Trial.

4

Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence.

Middleman MN, Lush RM, Sartor O, Reed E, Figg WD. Middleman MN, et al. Among authors: figg wd. Cancer Treat Rev. 1996 Mar;22(2):105-18. doi: 10.1016/s0305-7372(96)90030-4. Cancer Treat Rev. 1996. PMID: 8665563 Review. No abstract available.

5

The mutated androgen receptor and its implications for the treatment of metastatic carcinoma of the prostate.

Middleman MN, Lush RM, Figg WD. Middleman MN, et al. Among authors: figg wd. Pharmacotherapy. 1996 May-Jun;16(3):376-81. Pharmacotherapy. 1996. PMID: 8726595

6

Management of hormone-sensitive metastatic prostate cancer. Update on hormonal therapy.

Figg WD, Feuer JA, Bauer KS. Figg WD, et al. Cancer Pract. 1997 Jul-Aug;5(4):258-63. Cancer Pract. 1997. PMID: 9250085 Review. No abstract available.

7

A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer.

Thibault A, Figg WD, Bergan RC, Lush RM, Myers CE, Tompkins A, Reed E, Samid D. Thibault A, et al. Among authors: figg wd. Tumori. 1998 Jan-Feb;84(1):87-9. doi: 10.1177/030089169808400120. Tumori. 1998. PMID: 9619724 Clinical Trial.

8

A phase II study of bromocriptine in patients with androgen-independent prostate cancer.

Horti J, Figg WD, Weinberger B, Kohler D, Sartor O. Horti J, et al. Among authors: figg wd. Oncol Rep. 1998 Jul-Aug;5(4):893-6. doi: 10.3892/or.5.4.893. Oncol Rep. 1998. PMID: 9625840 Clinical Trial.

9

Pharmacokinetics of thalidomide in an elderly prostate cancer population.

Figg WD, Raje S, Bauer KS, Tompkins A, Venzon D, Bergan R, Chen A, Hamilton M, Pluda J, Reed E. Figg WD, et al. J Pharm Sci. 1999 Jan;88(1):121-5. doi: 10.1021/js980172i. J Pharm Sci. 1999. PMID: 9874712 Clinical Trial.

10

Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells.

Dixon SC, Kruger EA, Bauer KS, Figg WD. Dixon SC, et al. Among authors: figg wd. Cancer Chemother Pharmacol. 1999;43 Suppl:S78-84. doi: 10.1007/s002800051103. Cancer Chemother Pharmacol. 1999. PMID: 10357564

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

793 results

Search Page

Filters